Abstract
The formation of antianginal pharmacotherapy has gone a long way, characterized by the search for the main factors of effective pharmacodynamics. The article presents an analysis of the use of drugs with different pharmacological properties in patients suffering from angina pectoris in a historical aspect, shows the evolution of researchers’ ideas about the mechanism of antianginal action, and gives a brief description of modern antianginal drugs. Analysis of the features of drug treatment of chronic coronary insufficiency with angina attacks gives reason to say that the development of pharmacology in this section of cardiology is in the direction of improvement, first of all, in the pharmacokinetic aspect of already known drugs.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Reference27 articles.
1. 1. Korzh OM. Diahnostyka i likuvannia stabilnoi ishemichnoi khvoroby sertsia v praktytsi simeinoho likaria. Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny. 2019;2:63-68. Ukrainian
2. 2. Berger P. Ranolazine and Other Antianginal Therapies in the Era of the Drug-Eluting Stent. JAMA. 2004;291(3):365. http://dx.doi.org/10.1001/jama.291.3.365
3. 3. Knuuti J, Wijns W, Saraste A. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425.
4. 4. Gricjuk AI. Lekarstvennye sredstva v klinicheskoj kardiologii. Kiev: Zdorov'e; 1977. 296 р. Russian
5. 5. Franchi F, Padeletti L. Evaluation of the clinical electrophysiological effects of antianginal drugs without specific antiarrhythmic properties. Methods Find Exp Clin Pharmacol. 1981;3(1):17-27.